To recover your password please fill in your email address
Please fill in below form to create an account with us
ASCEND is a randomised, double blind Phase II study of LSTA1 (formerly CEND-1) with standard of care chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). LSTA1 is a novel agent which aims to improve delivery of chemotherapy treatments through the dense stroma of PDAC.
|
Trial Summary: |
To determine the effect of adding LSTA1 to standard of care chemotherapy with gemcitabine and nab‐paclitaxel on progression free survival (PFS) |
|
Supported By: |
Lisata Therapeutics (formerly CEND Therapeutics) |
|
Eligibility: |
Adults with histologically proven metastatic pancreatic ductal adenocarcinoma suitable for first line gemcitabine and nab‐paclitaxel chemotherapy. |
|
Registration ID: |
ACTRN12621001290886 |
|
Participation: |
Australia, New Zealand |
|
Australian Lead Group: |
AGITG |
|
Status: |
Recruiting |
|
Activation Date: |
13th April 2022 |
|
Chairs: |
A/Prof Andrew Dean and Prof Tim Price |
|
Contact: |
ascend.study@sydney.edu.au |